Company intelligence / Profile preview

SensaSure Technologies

U.S.

Ownership: Private
Development stage: Other

Overview

SensaSure Technologies developed and marketed ExaBreath, a non-invasive device for collecting, extracting, and identifying non-volatile compounds in exhaled breath, with applications in toxicology, disease detection, and substance monitoring. No clinical trial results as company was diagnostic-platform focused.

Therapeutic areas: Infectious DiseasesEndocrinologyMetabolic DisordersOther
Modalities: Device
Industry: Metabolite Diagnostics

Beyond the preview

Go deeper on SensaSure Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SensaSure Technologies.

Explore the full profile